Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
56M
-
Number of holders
-
179
-
Total 13F shares, excl. options
-
46.8M
-
Shares change
-
+4.57M
-
Total reported value, excl. options
-
$657M
-
Value change
-
+$61.8M
-
Put/Call ratio
-
1.34
-
Number of buys
-
106
-
Number of sells
-
-74
-
Price
-
$14.03
Significant Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) as of Q3 2015
202 filings reported holding SUPN - SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q3 2015.
SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) has 179 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.8M shares
of 56M outstanding shares and own 83.59% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.64M shares), BlackRock Fund Advisors (2.81M shares), STATE STREET CORP (1.96M shares), Invesco Ltd. (1.56M shares), Ranger Investment Management, L.P. (1.56M shares), Apex Capital Management (1.44M shares), VANGUARD GROUP INC (1.43M shares), GLENMEDE TRUST CO NA (1.19M shares), Murphy Michael R (1.03M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (979K shares).
This table shows the top 179 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.